Connor, Clark & Lunn Investment Management Ltd. Neurocrine Biosciences Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 248,633 shares of NBIX stock, worth $35.1 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

248,633

Previous 55,865 345.06%

Holding current value

$35.1 Million

Previous $6.18 Million 405.83%

% of portfolio

0.12%

Previous 0.03%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	$87.54 - $128.18 $16.9 Million - $24.7 Million	192,768 Added 345.06%	248,633 $31.3 Million
Q1 2025 May 12, 2025	SELL	$107.22 - $153.29 $827,416 - $1.18 Million	-7,717 Reduced 12.14%	55,865 $6.18 Million
Q4 2024 Feb 10, 2025	BUY	$111.62 - $139.44 $5.18 Million - $6.47 Million	46,396 Added 269.96%	63,582 $8.68 Million
Q3 2024 Nov 08, 2024	BUY	$114.58 - $153.15 $1.71 Million - $2.29 Million	14,956 Added 670.67%	17,186 $1.98 Million
Q2 2024 Aug 09, 2024	BUY	$130.86 - $143.19 $291,817 - $319,313	2,230 New	2,230 $307,000
Q4 2023 Feb 09, 2024	SELL	$106.07 - $132.76 $4.47 Million - $5.6 Million	-42,148 Reduced 60.15%	27,921 $3.68 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $8.67 Million - $10.8 Million	-92,200 Reduced 56.82%	70,069 $7.88 Million
Q2 2023 Aug 10, 2023	SELL	$89.53 - $104.87 $7.07 Million - $8.28 Million	-78,947 Reduced 32.73%	162,269 $15.3 Million
Q1 2023 May 09, 2023	BUY	$94.11 - $123.02 $6.08 Million - $7.95 Million	64,612 Added 36.59%	241,216 $24.4 Million
Q4 2022 Feb 10, 2023	SELL	$106.72 - $127.06 $2.21 Million - $2.63 Million	-20,704 Reduced 10.49%	176,604 $21.1 Million
Q3 2022 Nov 10, 2022	SELL	$92.03 - $107.81 $1.6 Million - $1.87 Million	-17,389 Reduced 8.1%	197,308 $21 Million
Q2 2022 Aug 05, 2022	BUY	$75.79 - $100.07 $386,377 - $510,156	5,098 Added 2.43%	214,697 $20.9 Million
Q1 2022 May 12, 2022	BUY	$72.45 - $94.81 $11.4 Million - $14.9 Million	157,512 Added 302.4%	209,599 $19.7 Million
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $4.15 Million - $5.53 Million	52,087 New	52,087 $4.44 Million
Q2 2021 Aug 12, 2021	SELL	$89.43 - $102.27 $410,125 - $469,010	-4,586 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $401,596 - $547,568	4,586 New	4,586 $446,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $912,468 - $1.14 Million	-10,499 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $1.01 Million - $1.42 Million	10,499 New	10,499 $1.01 Million
Q4 2018 Feb 12, 2019	SELL	$68.32 - $124.36 $203,251 - $369,971	-2,975 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $294,168 - $374,403	2,975 New	2,975 $366,000

Others Institutions Holding NBIX

# of Institutions

661

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Neurocrine Biosciences Inc Transaction History